{
  "company": {
    "name": "ImmunoACT (Immunoadoptive Cell Therapy Pvt. Ltd.)",
    "website": "https://immunoact.com/",
    "record": "https://startuphistory.org/c/immunoact.com"
  },
  "status": null,
  "history_since": "2021-08-14T13:48:12.000Z",
  "baseline": {
    "snapshot_id": "d553c34b12cad70aaa6070aca0fe31b23e509be32a640da7ac60e86b98afb143",
    "observed_at": "2021-08-14T13:48:12.000Z",
    "headline": "IIT Bombay spin-off company, incubated at SINE, driving India's first CAR-T cell therapy",
    "description": "Pioneer in India's first indigenous CAR-T cell therapy",
    "evidence": "https://web.archive.org/web/20210814134812/https://www.immunoact.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-06T17:22:41.701Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2025-07-09T17:02:40.000Z",
      "variants": [
        {
          "headline": "IIT Bombay spin-off company, incubated at SINE, driving India's first CAR-T cell therapy",
          "subhead": "Pioneer in India's first indigenous CAR-T cell therapy",
          "observed_at": "2021-08-14T13:48:12.000Z",
          "evidence": "https://web.archive.org/web/20210814134812/https://www.immunoact.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "ImmunoACT: an IIT Bombay spin-off company, incubated at SINE Driving India's first CAR-T cell therapy",
          "subhead": "Pioneer in India's first indigenous CAR-T cell therapy",
          "observed_at": "2022-01-27T05:18:59.000Z",
          "evidence": "https://web.archive.org/web/20220127051859/https://www.immunoact.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "ImmunoACT: an IIT Bombay spin-off company, incubated at SINE Driving India's first CAR-T cell therapy",
          "subhead": "Pioneer in India's first indigenous CAR-T cell therapy",
          "observed_at": "2022-08-13T14:44:32.000Z",
          "evidence": "https://web.archive.org/web/20220813144432/https://www.immunoact.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "ImmunoACT: an IIT Bombay spin-off company, incubated at SINE Driving India's first CAR-T cell therapy",
          "subhead": "Pioneer in India's first indigenous CAR-T cell therapy",
          "observed_at": "2023-02-06T02:21:56.000Z",
          "evidence": "https://web.archive.org/web/20230206022156/https://www.immunoact.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "ImmunoACT: an IIT Bombay spin-off company, incubated at SINE Driving India's first CAR-T cell therapy",
          "subhead": "ImmunoACT: India's first indigenous CAR-T therapy innovator",
          "observed_at": "2023-09-28T03:40:59.000Z",
          "evidence": "https://web.archive.org/web/20230928034059/https://www.immunoact.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "ImmunoACT, an IIT-Bombay spin-off incubated at SINE, is India's first gene-modified cell therapy company, fully integrated from R&D to Manufacturing and Commercialization. Our goal is bringing innovat",
          "subhead": "ImmunoACT: India's first indigenous CAR-T therapy innovator",
          "observed_at": "2024-07-12T00:37:26.000Z",
          "evidence": "https://web.archive.org/web/20240712003726/https://www.immunoact.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "ImmunoACT, an IIT-Bombay spin-off incubated at SINE, is India's first gene-modified cell therapy company, fully integrated from R&D to Manufacturing and Commercialization. Our goal is bringing innovat",
          "subhead": "ImmunoACT: India's first indigenous CAR-T therapy innovator",
          "observed_at": "2025-01-07T03:24:48.000Z",
          "evidence": "https://web.archive.org/web/20250107032448/https://www.immunoact.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "India’s 1st Indigenous CAR-T Cell Therapy",
          "subhead": "India’s 1st Indigenous CAR-T Cell Therapy Impact of NexCAR 19 90% Remission Rate 200+ Patients Treated 2x Likely To Stay Cancer-free 2yrs Longest Remission Rate Our Manufacturing Facility Harnessing Y",
          "observed_at": "2025-07-09T17:02:40.000Z",
          "evidence": "https://web.archive.org/web/20250709170240/https://immunoact.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "India’s 1st Indigenous CAR-T Cell Therapy",
      "subhead": "India’s 1st Indigenous CAR-T Cell Therapy Impact of NexCAR 19 90% Remission Rate 200+ Patients Treated 2x Likely To Stay Cancer-free 2yrs Longest Remission Rate Our Manufacturing Facility Harnessing Y",
      "from": "2021-08-14T13:48:12.000Z",
      "to": "2025-07-09T17:02:40.000Z",
      "captures": 8,
      "evidence": "https://web.archive.org/web/20250709170240/https://immunoact.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2021-08-14T13:48:12.000Z",
          "to": "2025-07-09T17:02:40.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-01-17T06:39:22.000Z",
      "variants": [
        {
          "headline": "Celebrating 2 Years of Transforming Lives",
          "subhead": "ImmunoACT delivers India’s leading CAR-T cell therapy for blood cancer treatment, lymphoma treatment, and leukemia care. Learn how indigenous CAR-T advances affordable cancer treatment nationwide.",
          "observed_at": "2026-01-17T06:39:22.000Z",
          "evidence": "https://web.archive.org/web/20260117063922/https://immunoact.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Celebrating 2 Years of Transforming Lives",
      "subhead": "ImmunoACT delivers India’s leading CAR-T cell therapy for blood cancer treatment, lymphoma treatment, and leukemia care. Learn how indigenous CAR-T advances affordable cancer treatment nationwide.",
      "from": "2026-01-17T06:39:22.000Z",
      "to": "2026-01-17T06:39:22.000Z",
      "captures": 1,
      "evidence": "https://web.archive.org/web/20260117063922/https://immunoact.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "on": "2026-01-17T06:39:22.000Z"
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-06T17:22:41.701Z",
      "variants": [
        {
          "headline": "ImmunoACT partners with Cipla to launch Talicabtagene autoleucel in Africa",
          "subhead": "ImmunoACT delivers India’s leading CAR-T cell therapy for blood cancer treatment, lymphoma treatment, and leukemia care. Learn how indigenous CAR-T advances affordable cancer treatment nationwide.",
          "observed_at": "2026-07-16T05:07:26.000Z",
          "evidence": "https://web.archive.org/web/20260716050726/https://immunoact.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "ImmunoACT partners with Cipla to launch Talicabtagene autoleucel in Africa",
          "subhead": "ImmunoACT delivers India’s leading CAR-T cell therapy for blood cancer treatment, lymphoma treatment, and leukemia care. Learn how indigenous CAR-T advances affordable cancer treatment nationwide.",
          "observed_at": "2026-11-06T17:22:41.701Z",
          "evidence": "https://immunoact.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "ImmunoACT partners with Cipla to launch Talicabtagene autoleucel in Africa",
      "subhead": "ImmunoACT delivers India’s leading CAR-T cell therapy for blood cancer treatment, lymphoma treatment, and leukemia care. Learn how indigenous CAR-T advances affordable cancer treatment nationwide.",
      "from": "2026-07-16T05:07:26.000Z",
      "to": "2026-11-06T17:22:41.701Z",
      "captures": 2,
      "evidence": "https://immunoact.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2026-07-16T05:07:26.000Z",
          "to": "2026-11-06T17:22:41.701Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-5b166c0b9f5e14e043c145395740024dddb68f2b286a40ca49415b92284917c2:7361bb4141df9dc5dee63f0ddbf22716f6061832184d1011d1c75b465357677e:headline:22a6ae813380da37",
      "before_evidence": "https://web.archive.org/web/20250107032448/https://www.immunoact.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “ImmunoACT, an IIT-Bombay spin-off incubated at SINE, is India's first gene-modified cell therapy company, fully integrated from R&D to Ma…” to “India’s 1st Indigenous CAR-T Cell Therapy”.",
      "between": {
        "from": "2025-01-07T03:24:48.000Z",
        "to": "2025-07-09T17:02:40.000Z"
      },
      "evidence": "https://web.archive.org/web/20250709170240/https://immunoact.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 2,
      "id": "page-5b166c0b9f5e14e043c145395740024dddb68f2b286a40ca49415b92284917c2:7361bb4141df9dc5dee63f0ddbf22716f6061832184d1011d1c75b465357677e:hiring:20dd4c09cc4ab0aa",
      "before_evidence": "https://web.archive.org/web/20250107032448/https://www.immunoact.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "hiring",
      "label": "Hiring",
      "summary": "Added a careers page.",
      "between": {
        "from": "2025-01-07T03:24:48.000Z",
        "to": "2025-07-09T17:02:40.000Z"
      },
      "evidence": "https://web.archive.org/web/20250709170240/https://immunoact.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-careers-page"
    },
    {
      "n": 3,
      "id": "page-7361bb4141df9dc5dee63f0ddbf22716f6061832184d1011d1c75b465357677e:e246a7e47b655887ebef0a1ca2b7924fcb21b6a25563d1d6769aa8f547becbcd:headline:d0c48c7cb93ffc36",
      "before_evidence": "https://web.archive.org/web/20250709170240/https://immunoact.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “India’s 1st Indigenous CAR-T Cell Therapy” to “Celebrating 2 Years of Transforming Lives”.",
      "between": {
        "from": "2025-07-09T17:02:40.000Z",
        "to": "2026-01-17T06:39:22.000Z"
      },
      "evidence": "https://web.archive.org/web/20260117063922/https://immunoact.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 4,
      "id": "page-e246a7e47b655887ebef0a1ca2b7924fcb21b6a25563d1d6769aa8f547becbcd:565bebeacc3b59db4bd2c2e048517919df503653c891e9f4f82fd4097d09deb1:headline:a20effe5c006f24b",
      "before_evidence": "https://web.archive.org/web/20260117063922/https://immunoact.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Celebrating 2 Years of Transforming Lives” to “ImmunoACT partners with Cipla to launch Talicabtagene autoleucel in Africa”.",
      "between": {
        "from": "2026-01-17T06:39:22.000Z",
        "to": "2026-07-16T05:07:26.000Z"
      },
      "evidence": "https://web.archive.org/web/20260716050726/https://immunoact.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “ImmunoACT (Immunoadoptive Cell Therapy Pvt. Ltd.)” company record, https://startuphistory.org/c/immunoact.com"
}